Toggle navigation
Pipeline
Pipeline
Pipeline Chart
Validive
Overview
Severe Oral Mucositis and Oropharyngeal Cancer
Phase 2 Data Supports Further Development in OPC
MNPR-301-001 Clinical Trial
Camsirubicin
Overview
Clinical Data
Development Strategy
MNPR-201-001 Clinical Trial
MNPR-101 RIT
MNPR-101
Overview
Development Strategy
MNPR-202
Collaborations
Overview
Current Collaborations
Intellectual Property
Publications
Validive
Camsirubicin
MNPR-101
Investors
Investors
Overview
Annual Meeting
News / Events
Press Releases
IR Calendar
In the News
Email Alerts
Company Information
Profile
Presentations
Our Team
FAQ
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Documents
Our Team
Our Team
Contact Us
Contact Us
SIV Materials
SIV Materials
Home
Investors
SEC Filings
All SEC Filings
Investors
Investors
Overview
Annual Meeting
News / Events
Press Releases
IR Calendar
In the News
Email Alerts
Company Info
Profile
Presentations
Our Team
FAQ
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Board of Directors
Board Committees
Governance Documents
Investor Tools
Email Alerts
Tear Sheet
Contacts
RSS News Feed
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
All SEC Filings
Filing Type:
View All
10-12G
10-12G/A
10-K
10-K/A
10-Q
10-Q/A
3
3/A
4
4/A
424B4
424B5
8-A12B
8-K
CERT
CORRESP
CT ORDER
D
DEF 14A
DEF 14C
DEFA14A
EFFECT
FWP
S-1
S-1/A
S-3
S-8
SC 13D
UPLOAD
Year:
View All
2022
2021
2020
2019
2018
2017
2016
2015
Date
Form
Description
PDF
XBRL
Pages
01/03/20
S-8
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Documents
EX-5
EX-23
9
12/23/19
SC 13D
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
12
12/23/19
SC 13D
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
13
12/20/19
4
Statement of changes in beneficial ownership of securities
2
12/20/19
4
Statement of changes in beneficial ownership of securities
2
12/20/19
4
Statement of changes in beneficial ownership of securities
2
12/20/19
4
Statement of changes in beneficial ownership of securities
2
12/19/19
424B4
Prospectus filed pursuant to Rule 424(b)(4)
157
12/18/19
EFFECT
Notice of Effectiveness
1
12/17/19
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
11
12
13
14
15
16
17
18
19
20